1165 related articles for article (PubMed ID: 22686416)
1. Basal insulin and cardiovascular and other outcomes in dysglycemia.
; Gerstein HC; Bosch J; Dagenais GR; Díaz R; Jung H; Maggioni AP; Pogue J; Probstfield J; Ramachandran A; Riddle MC; Rydén LE; Yusuf S
N Engl J Med; 2012 Jul; 367(4):319-28. PubMed ID: 22686416
[TBL] [Abstract][Full Text] [Related]
2. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
; Bosch J; Gerstein HC; Dagenais GR; Díaz R; Dyal L; Jung H; Maggiono AP; Probstfield J; Ramachandran A; Riddle MC; Rydén LE; Yusuf S
N Engl J Med; 2012 Jul; 367(4):309-18. PubMed ID: 22686415
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Marso SP; McGuire DK; Zinman B; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Haahr PM; Lange M; Brown-Frandsen K; Moses A; Skibsted S; Kvist K; Buse JB;
N Engl J Med; 2017 Aug; 377(8):723-732. PubMed ID: 28605603
[TBL] [Abstract][Full Text] [Related]
4. Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial.
Cukierman-Yaffe T; Bosch J; Diaz R; Dyal L; Hancu N; Hildebrandt P; Lanas F; Lewis BS; Marre M; Yale JF; Yusuf S; Gerstein HC;
Lancet Diabetes Endocrinol; 2014 Jul; 2(7):562-72. PubMed ID: 24898834
[TBL] [Abstract][Full Text] [Related]
5. Effect of nateglinide on the incidence of diabetes and cardiovascular events.
; Holman RR; Haffner SM; McMurray JJ; Bethel MA; Holzhauer B; Hua TA; Belenkov Y; Boolell M; Buse JB; Buckley BM; Chacra AR; Chiang FT; Charbonnel B; Chow CC; Davies MJ; Deedwania P; Diem P; Einhorn D; Fonseca V; Fulcher GR; Gaciong Z; Gaztambide S; Giles T; Horton E; Ilkova H; Jenssen T; Kahn SE; Krum H; Laakso M; Leiter LA; Levitt NS; Mareev V; Martinez F; Masson C; Mazzone T; Meaney E; Nesto R; Pan C; Prager R; Raptis SA; Rutten GE; Sandstroem H; Schaper F; Scheen A; Schmitz O; Sinay I; Soska V; Stender S; Tamás G; Tognoni G; Tuomilehto J; Villamil AS; Vozár J; Califf RM
N Engl J Med; 2010 Apr; 362(16):1463-76. PubMed ID: 20228402
[TBL] [Abstract][Full Text] [Related]
6. Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial.
; Gilbert RE; Mann JF; Hanefeld M; Spinas G; Bosch J; Yusuf S; Gerstein HC
Diabetologia; 2014 Jul; 57(7):1325-31. PubMed ID: 24771090
[TBL] [Abstract][Full Text] [Related]
7. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
Rosenstock J; Bain SC; Gowda A; Jódar E; Liang B; Lingvay I; Nishida T; Trevisan R; Mosenzon O;
N Engl J Med; 2023 Jul; 389(4):297-308. PubMed ID: 37356066
[TBL] [Abstract][Full Text] [Related]
8. Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE).
Lonn EM; Bosch J; Diaz R; Lopez-Jaramillo P; Ramachandran A; Hâncu N; Hanefeld M; Krum H; Ryden L; Smith S; McQueen MJ; Dyal L; Yusuf S; Gerstein HC;
Diabetes Care; 2013 Sep; 36(9):2466-74. PubMed ID: 23564916
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE).
ORIGIN Trial Investigators
Diabetes Care; 2016 May; 39(5):709-16. PubMed ID: 26681720
[TBL] [Abstract][Full Text] [Related]
10. Effect of valsartan on the incidence of diabetes and cardiovascular events.
; McMurray JJ; Holman RR; Haffner SM; Bethel MA; Holzhauer B; Hua TA; Belenkov Y; Boolell M; Buse JB; Buckley BM; Chacra AR; Chiang FT; Charbonnel B; Chow CC; Davies MJ; Deedwania P; Diem P; Einhorn D; Fonseca V; Fulcher GR; Gaciong Z; Gaztambide S; Giles T; Horton E; Ilkova H; Jenssen T; Kahn SE; Krum H; Laakso M; Leiter LA; Levitt NS; Mareev V; Martinez F; Masson C; Mazzone T; Meaney E; Nesto R; Pan C; Prager R; Raptis SA; Rutten GE; Sandstroem H; Schaper F; Scheen A; Schmitz O; Sinay I; Soska V; Stender S; Tamás G; Tognoni G; Tuomilehto J; Villamil AS; Vozár J; Califf RM
N Engl J Med; 2010 Apr; 362(16):1477-90. PubMed ID: 20228403
[TBL] [Abstract][Full Text] [Related]
11. Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial.
ORIGIN Trial Investigators
Diabetes Care; 2015 Jan; 38(1):22-8. PubMed ID: 25352653
[TBL] [Abstract][Full Text] [Related]
12. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.
Pratley RE; Husain M; Lingvay I; Pieber TR; Mark T; Saevereid HA; Møller DV; Zinman B;
Cardiovasc Diabetol; 2019 Nov; 18(1):156. PubMed ID: 31729990
[TBL] [Abstract][Full Text] [Related]
13. Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study.
Papademetriou V; Nylen ES; Doumas M; Probstfield J; Mann JFE; Gilbert RE; Gerstein HC
Am J Med; 2017 Dec; 130(12):1465.e27-1465.e39. PubMed ID: 28842165
[TBL] [Abstract][Full Text] [Related]
14. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
[TBL] [Abstract][Full Text] [Related]
15. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial.
; Mellbin LG; Rydén L; Riddle MC; Probstfield J; Rosenstock J; Díaz R; Yusuf S; Gerstein HC
Eur Heart J; 2013 Oct; 34(40):3137-44. PubMed ID: 23999452
[TBL] [Abstract][Full Text] [Related]
16. The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial.
Rautio A; Boman K; Gerstein HC; Hernestål-Boman J; Lee SF; Olofsson M; Mellbin LG
Diab Vasc Dis Res; 2017 Jul; 14(4):345-352. PubMed ID: 28403644
[TBL] [Abstract][Full Text] [Related]
17. ORIGIN trial shows safety and efficacy of insulin glargine: no adverse cardiovascular outcomes after a 6.2-year follow up of early insulin use.
Lombard L; Distiller L; Aalbers J
Cardiovasc J Afr; 2012 Jul; 23(6):357-8. PubMed ID: 23091824
[No Abstract] [Full Text] [Related]
18. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).
; Gerstein H; Yusuf S; Riddle MC; Ryden L; Bosch J
Am Heart J; 2008 Jan; 155(1):26-32, 32.e1-6. PubMed ID: 18082485
[TBL] [Abstract][Full Text] [Related]
19. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia.
Bordeleau L; Yakubovich N; Dagenais GR; Rosenstock J; Probstfield J; Chang Yu P; Ryden LE; Pirags V; Spinas GA; Birkeland KI; Ratner RE; Marin-Neto JA; Keltai M; Riddle MC; Bosch J; Yusuf S; Gerstein HC;
Diabetes Care; 2014; 37(5):1360-6. PubMed ID: 24574355
[TBL] [Abstract][Full Text] [Related]
20. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
